Aortic Valve DiseaseREVIVAL-RegNCT03894787
Ross for Valve Replacement in Adults - Registry
An observational study of Aortic Valve Disease, run by Population Health Research Institute at 1 site in Canada.
Trial summary
This registry follows patients undergoing two methods of aortic heart valve replacement in adults aged 18-60, the Ross procedure or conventional aortic valve replacement using a biologic or mechanical heart valve. Read more about this study
- Who is it for?
- Ages 18 to 60 years
- Conditions the study is for
- Aortic Valve Disease
- How many people
- 62 participants
- Where
- 1 siteCanada
- Study dates
- 3 Jun 2019to 22 Dec 2023
- How long will I take part?
- 2 Years
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 60 years
- All sexes
- No healthy volunteers
- Adult
Study population: All patients who meet eligibility criteria of the REVIVAL trial, but are not included in the trial due to patient or clinician factors, will be asked to participate in the REVIVAL registry.
Who may be able to join
- Age 18-60 years
- Undergoing clinically indicated aortic valve replacement
- Provided written informed consent
Who cannot join
- Previous valve replacement not in the aortic position
- Patients undergoing concomitant CABG or other valve procedure during aortic valve replacement
- Known connective tissue disease
- Severe (grade 3 or 4) right or left ventricular dysfunction
- Pulmonary valve dysfunction or anomaly not compatible with the Ross procedure (as determined by the consulting cardiac surgeon)
- Life expectancy less than 5 years (as determined by the consulting cardiac surgeon)
- Documented severe aortic insufficiency not solely due to leaflet issue
- Previous intervention on the pulmonary valve
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Ross for Valve Replacement in AduLts (REVIVAL) Registry
This registry follows patients undergoing two methods of aortic heart valve replacement in adults aged 18-60, the Ross procedure or conventional aortic valve replacement using a biologic or mechanical heart valve. The Ross procedure replaces a patient's diseased aortic valve with his/her own pulmonary valve and uses a donor valve in the pulmonary position which receives less stress than the aortic valve. Mechanical valves tend to form blood clots so they need long-term blood thinners that increase risk of bleeding and lower quality of life. Animal tissue valves reduce clotting and bleeding risks but wear out sooner and shorten patient life-span. The REVIVAL Registry will run in parallel with the REVIVAL randomized trial.
Read the detailed description
Heart valves help control blood flow through the heart and, if diseased, may need to be replaced. After having a heart valve replaced, patients have a higher risk of death than people who have not had a valve replaced. In young adult patients, replacing the aortic heart valve with a mechanical valve halves their life-span compared to other people their age. Mechanical valves tend to form blood clots so they need long-term blood thinners that increase risk of bleeding and lower quality of life. Animal tissue valves reduce clotting and bleeding risks but wear out sooner and shorten patient life-span. An operation, called the Ross procedure, replaces a patient's diseased aortic valve with his/her own pulmonary valve and uses a donor valve in the pulmonary position which receives less stress than the aortic valve. The Ross procedure aims to improve valve durability with less clotting, avoiding use of blood thinners. Patients and physicians need a large, high-quality study comparing the Ross procedure and standard valve replacement to know if either approach is better. In parallel to the REVIVAL Registry, a REVIVAL Randomized Trial will also take place.
Patients included in randomized trials often systematically differ from those who are not. By creating a registry of patients who are eligible for but not recruited into the REVIVAL trial, the investigators will better understand: 1) the reasons for not including these patients; 2) how those patients differ in terms of baseline characteristics from the trial cohort; 3) whether the outcomes of registry participants differ from those in the trial, assessed by treatment group. The registry will aid in understanding the generalizability of the results that the trial produces.
- Conditions
- Aortic Valve Disease
- Keywords
- Ross procedure, Conventional aortic valve replacement
- Medical subject headings
- Aortic Valve Disease
What is being measured
The primary outcome is the main question the study is designed to answer.
Evaluation of systematic differences between registry and trial patients
The primary outcome of the REVIVAL registry is to examine for systematic differences between the demographics and outcomes of patients enrolled in the REVIVAL trial and patients not enrolled in the trial.
We will use descriptive statistics including mean (standard deviation), median (interquartile range), and count (proportion) to describe the REVIVAL registry cohort.
Measured: Through REVIVAL Trial completion, estimated to be 10 years
Secondary outcomes (16)
Evaluate the number of patients meeting eligibility criteria for the REVIVAL trial per month who are not enrolled into the trial.
To determine the number of eligible patients and reasons why they were not enrolled into the REVIVAL trial.
Measured: Through completion of the pilot trial, estimated to be 3 years
Evaluate the proportion of Ross procedures compared to conventional aortic valve replacement.
Measure the proportions of type of mechanical valve versus biological valves versus Ross procedure in the REVIVAL registry participants.
Measured: Through completion of the pilot trial, estimated to be 3 years
The rate of survival free of a composite of life-threatening valve-related complications (major bleeding, stroke or systemic thromboembolism, valve thrombosis, and operated-on valve reintervention)
Evaluate the frequency of REVIVAL trial outcomes among registry participants.
The primary outcome is the rate of survival free of life-threatening valve-related complications (major bleeding, stroke or systemic thromboembolism, valve thrombosis, and operated-on valve reintervention) over duration of follow-up. Assessment of this composite over time is particularly important, as the Ross procedure may show initial benefit secondary to thromboembolic and bleeding reduction, however should the technique show high late rates of reoperation as suggested in some observational literature, the effect magnitude may change significantly over time.
Measured: Through trial completion, estimated to be 10 years
The rate of perioperative and non-perioperative major bleeding over the duration of patient follow-up.
Evaluate the frequency of REVIVAL trial outcomes among REVIVAL registry participants.
Perioperative (index surgery only) Intraoperative: After administration of protamine, delay of chest closure for bleeding > 500 mL/hr requiring packing and transfusion of more than 3 units red blood cells /whole blood.
Upon leaving OR to 48hrs postop (modified BARC type 4)
Intracranial bleeding within 48hrs Reoperation after sternum closure for purpose of controlling bleeding or relief of tamponade Transfusion of ≥ 5 units packed red blood cells /whole blood in the 48hr period Chest tube output ≥ 2L in the first 24hr Non-perioperative Per the International Society of Thrombosis and Hemostasis (ISTH) major bleeding definition.
Measured: Through trial completion, estimated to be 10 years
The rate of stroke or systemic thromboembolism over the duration of patient follow-up.
Evaluate the frequency of REVIVAL trial outcomes among REVIVAL registry participants.
Stroke is acute focal brain dysfunction due to a vascular cause lasting ≥ 24 hrs in the absence of brain imaging or requires evidence of acute stroke on brain imaging. Stroke is divided into 3 types: ischemic stroke, hemorrhagic stroke, and undetermined stroke. If death occurs within 24 hours, the neurological deficit must persist up to the time of death.
Systemic arterial embolism is an abrupt vascular insufficiency associated with evidence of arterial occlusion in the absence of other likely mechanisms. Clinical signs/symptoms must be consistent with embolic arterial occlusion, there must be clear evidence of abrupt occlusion of a systemic artery, with at least one type of supporting evidence (surgical report indicating evidence of arterial embolism, pathological specimens related to embolism removal, imaging evidence consistent with arterial embolism, or autopsy report).
Measured: Through trial completion, estimated to be 10 years
The rate of valve thrombosis per VARC criteria over the duration of patient follow-up.
Evaluate the frequency of REVIVAL trial outcomes among REVIVAL registry participants.
Valve thrombosis is defined as any thrombus not caused by infection attached to or near an operated valve that occludes part of the blood flow path, interferes with valve function, or is large enough to warrant treatment. Valve thrombus found at autopsy in a patient whose cause of death was not valve related or found at operation for and unrelated indication is to be counted as valve thrombosis.
Measured: Through trial completion, estimated to be 10 years
The rate of operated-on valve reintervention over the duration of patient follow-up.
Evaluate the frequency of REVIVAL trial outcomes among REVIVAL registry participants.
Rate of valve reintervention Any surgical or percutaneous procedure that repairs, or otherwise alters or adjusts, or replaces a previously implanted prosthesis or valve.
Measured: Through trial completion, estimated to be 10 years
Rate of mortality within 30 days post-operatively.
Evaluate the frequency of REVIVAL trial outcomes among REVIVAL registry participants.
Measured: 30 days
Measure health related quality of life using the 36-Item Short Form Survey (SF-36) questionnaire over the duration of patient follow-up
Evaluate the frequency of REVIVAL trial outcomes among REVIVAL registry participants.
The 36-Item Short Form Survey (SF-36) is a health related quality of life questionnaire that measure eight health domains and each survey provides psychometrically-based physical component summary (PCS) and mental component summary (MCS) scores. The domains are physical functioning, bodily pain, role limitations due to physical health problems, role limitations due to personal or emotional problems, emotional well-being, social functioning, energy/fatigue, and general health perceptions. The questionnaire is calibrated such that scored values of 50 represent the norm and higher scored values according to the scoring key represent a more favourable health state. A baseline score will be obtained prior to the patient's surgery and the SF-36 will be administered annually thereafter over the duration of patient follow-up.
Measured: Through trial completion, estimated to be 10 years
The rate of operated-valve endocarditis over the duration of patient follow-up
Evaluate the frequency of REVIVAL trial outcomes among REVIVAL registry participants.
Defined as any infection involving a valve on which an operation has been performed. The diagnosis is based on one or more of the following: 1) reoperation with evidence of abscess, paravalvular leak, pus, or vegetation confirmed as secondary to infection by histologic or bacteriologic studies; 2) autopsy findings of abscess, pus, or vegetation involving an operated-on valve; or 3) the meeting of Duke criteria for endocarditis.
Measured: Through trial completion, estimated to be 10 years
The rate of aortic valve re-intervention over the duration of patient follow-up.
Evaluate the frequency of REVIVAL trial outcomes among REVIVAL registry participants
Any surgical or percutaneous procedure that repairs, or otherwise alters or adjusts, or replaces a previously implanted prosthesis or valve in the aortic position.
Measured: Through trial completion, estimated to be 10 years
The rate of pulmonary valve re-intervention over the duration of patient follow-up.
Evaluate the frequency of REVIVAL trial outcomes among REVIVAL registry participants
Any surgical or percutaneous procedure that repairs, or otherwise alters or adjusts, or replaces a previously implanted prosthesis or valve in the pulmonary position.
Measured: Through trial completion, estimated to be 10 years
Mean aortic valve gradient.
Evaluate the frequency of REVIVAL trial outcomes among REVIVAL registry participants.
Measured through echocardiography
Measured: Through trial completion, estimated to be 10 years
Mean pulmonic valve gradient
Evaluate the frequency of REVIVAL trial outcomes among REVIVAL registry participants.
Measured through echocardiography
Measured: Through trial completion, estimated to be 10 years
Severity of aortic valve regurgitation.
Evaluate the frequency of REVIVAL trial outcomes among REVIVAL registry participants.
Measured through echocardiography, categorized as mild, moderate, or severe
Measured: Through trial completion, estimated to be 10 years
Severity of pulmonic valve regurgitation
Evaluate the frequency of REVIVAL trial outcomes among REVIVAL registry participants.
Measured through echocardiography, categorized as mild, moderate, or severe
Measured: Through trial completion, estimated to be 10 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 Mar 2019
- Study start3 Jun 2019
- Primary completion1 Oct 2022
- Study completion22 Dec 2023
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Aortic Valve DiseaseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 62 participants (actual)
- Target duration
- 2 Years
Sponsor and investigators
- Lead sponsor
- Population Health Research Institute
- Sponsor type
- University, hospital or other
- Collaborators
- Hamilton Health Sciences Corporation
- Responsible party
- Sponsor
- Investigators
- Richard Whitlock, MD, PhD, Principal investigator, Population Health Research Institute
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03894787
- Sponsor's protocol ID
- REVIVAL Reg - 2018
- Acronym
- REVIVAL-Reg
- Status last verified
- Jan 2024
- First submitted
- 22 Mar 2019
- Last updated
- 31 Jan 2024
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 31 Jan 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Ross for Valve Replacement in AduLts (REVIVAL) Registry
- ClinicalTrials.gov ID
- NCT03894787
- Acronym / sponsor ID
- REVIVAL-Reg / REVIVAL Reg - 2018
- Conditions
- Aortic Valve Disease
- Keywords
- Ross procedure, Conventional aortic valve replacement
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 62 participants (actual)
- Lead sponsor
- Population Health Research InstituteUniversity, hospital or other
- Collaborators
- Hamilton Health Sciences Corporation
- Study start
- 3 Jun 2019 (actual)
- Primary completion
- 1 Oct 2022 (actual)
- Study completion
- 22 Dec 2023 (actual)
- First posted
- 29 Mar 2019 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This registry follows patients undergoing two methods of aortic heart valve replacement in adults aged 18-60, the Ross procedure or conventional aortic valve replacement using a biologic or mechanical heart valve. The Ross procedure replaces a patient's diseased aortic valve with his/her own pulmonary valve and uses a donor valve in the pulmonary position which receives less stress than the aortic valve. Mechanical valves tend to form blood clots so they need long-term blood thinners that increase risk of bleeding and lower quality of life. Animal tissue valves reduce clotting and bleeding risks but wear out sooner and shorten patient life-span. The REVIVAL Registry will run in parallel with the REVIVAL randomized trial.
Detailed description
Heart valves help control blood flow through the heart and, if diseased, may need to be replaced. After having a heart valve replaced, patients have a higher risk of death than people who have not had a valve replaced. In young adult patients, replacing the aortic heart valve with a mechanical valve halves their life-span compared to other people their age. Mechanical valves tend to form blood clots so they need long-term blood thinners that increase risk of bleeding and lower quality of life. Animal tissue valves reduce clotting and bleeding risks but wear out sooner and shorten patient life-span. An operation, called the Ross procedure, replaces a patient's diseased aortic valve with his/her own pulmonary valve and uses a donor valve in the pulmonary position which receives less stress than the aortic valve. The Ross procedure aims to improve valve durability with less clotting, avoiding use of blood thinners. Patients and physicians need a large, high-quality study comparing the Ross procedure and standard valve replacement to know if either approach is better. In parallel to the REVIVAL Registry, a REVIVAL Randomized Trial will also take place.
Patients included in randomized trials often systematically differ from those who are not. By creating a registry of patients who are eligible for but not recruited into the REVIVAL trial, the investigators will better understand: 1) the reasons for not including these patients; 2) how those patients differ in terms of baseline characteristics from the trial cohort; 3) whether the outcomes of registry participants differ from those in the trial, assessed by treatment group. The registry will aid in understanding the generalizability of the results that the trial produces.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 2 Years
Who may qualify
- Ages
- 18 to 60 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
- Study population
- All patients who meet eligibility criteria of the REVIVAL trial, but are not included in the trial due to patient or clinician factors, will be asked to participate in the REVIVAL registry.
Key inclusion criteria (3 listed)
- Age 18-60 years
- Undergoing clinically indicated aortic valve replacement
- Provided written informed consent
Key exclusion criteria (8 listed)
- Previous valve replacement not in the aortic position
- Patients undergoing concomitant CABG or other valve procedure during aortic valve replacement
- Known connective tissue disease
- Severe (grade 3 or 4) right or left ventricular dysfunction
- Pulmonary valve dysfunction or anomaly not compatible with the Ross procedure (as determined by the consulting cardiac surgeon)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Evaluation of systematic differences between registry and trial patients
Time frame: Through REVIVAL Trial completion, estimated to be 10 years
The primary outcome of the REVIVAL registry is to examine for systematic differences between the demographics and outcomes of patients enrolled in the REVIVAL trial and patients not enrolled in the trial. We will use descriptive statistics including mean (standard deviation), median (interquartile range), and count (proportion) to describe the REVIVAL registry cohort.
16 secondary outcomes
Evaluate the number of patients meeting eligibility criteria for the REVIVAL trial per month who are not enrolled into the trial.
Time frame: Through completion of the pilot trial, estimated to be 3 years
Evaluate the proportion of Ross procedures compared to conventional aortic valve replacement.
Time frame: Through completion of the pilot trial, estimated to be 3 years
The rate of survival free of a composite of life-threatening valve-related complications (major bleeding, stroke or systemic thromboembolism, valve thrombosis, and operated-on valve reintervention)
Time frame: Through trial completion, estimated to be 10 years
The rate of perioperative and non-perioperative major bleeding over the duration of patient follow-up.
Time frame: Through trial completion, estimated to be 10 years
The rate of stroke or systemic thromboembolism over the duration of patient follow-up.
Time frame: Through trial completion, estimated to be 10 years
The rate of valve thrombosis per VARC criteria over the duration of patient follow-up.
Time frame: Through trial completion, estimated to be 10 years
The rate of operated-on valve reintervention over the duration of patient follow-up.
Time frame: Through trial completion, estimated to be 10 years
Rate of mortality within 30 days post-operatively.
Time frame: 30 days
Measure health related quality of life using the 36-Item Short Form Survey (SF-36) questionnaire over the duration of patient follow-up
Time frame: Through trial completion, estimated to be 10 years
The rate of operated-valve endocarditis over the duration of patient follow-up
Time frame: Through trial completion, estimated to be 10 years
The rate of aortic valve re-intervention over the duration of patient follow-up.
Time frame: Through trial completion, estimated to be 10 years
The rate of pulmonary valve re-intervention over the duration of patient follow-up.
Time frame: Through trial completion, estimated to be 10 years
Mean aortic valve gradient.
Time frame: Through trial completion, estimated to be 10 years
Mean pulmonic valve gradient
Time frame: Through trial completion, estimated to be 10 years
Severity of aortic valve regurgitation.
Time frame: Through trial completion, estimated to be 10 years
Severity of pulmonic valve regurgitation
Time frame: Through trial completion, estimated to be 10 years
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 31 Jan 2024.
Related trials for Aortic Valve Disease
Recruiting
SYMmetric Valve fraME Expansion To Reduce hYpoattenuated Leaflet Thickening After Balloon-expandable TAVI: the SYMMETRY Trial
Aortic Valve Stenosis and/or Insufficiency, Hypoattenuated Leaflet Thickening
RecruitingObservational study
Spanish Prospective Registry of Hydra THV for Transcatheter Aortic Valve Implantation
Severe Aortic Valve Stenosis, Valvular Heart Disease
Active, not recruiting
JOURNEY LVAD: JOURNEY Left Ventricular Assist Device
Aortic Valve Regurgitation, Aortic Valve Disease Mixed
RecruitingObservational study
Korea VHD Echo Study: Surveillance of Aortic, Mitral & Tricuspid Patients - Insights From Real-world Practice
Heart Valve Diseases, Aortic Valve Stenosis
Not yet recruiting
Human Experimental Models of Pain (HEMP)
Acute Pain
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Richard Whitlock, MD, PhD principal investigator
Population Health Research Institute
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Aortic Valve Disease, run by Population Health Research Institute at 1 site in Canada.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 31 Jan 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Evaluation of systematic differences between registry and trial patients (time frame: Through REVIVAL Trial completion, estimated to be 10 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 31 Jan 2024.